TY  - JOUR
AU  - Emde-Rajaratnam, Martina
AU  - Beck, Susanne
AU  - Benes, Vladimir
AU  - Salwender, Hans
AU  - Bertsch, Uta
AU  - Scheid, Christoph
AU  - Hänel, Mathias
AU  - Weisel, Katja
AU  - Hielscher, Thomas
AU  - Raab, Marc S
AU  - Goldschmidt, Hartmut
AU  - Jauch, Anna
AU  - Maes, Ken
AU  - De Bruyne, Elke
AU  - Menu, Eline
AU  - De Veirman, Kim
AU  - Moreaux, Jérôme
AU  - Vanderkerken, Karin
AU  - Seckinger, Anja
AU  - Hose, Dirk
TI  - RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
JO  - Frontiers in immunology
VL  - 14
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2023-02521
SP  - 1286700
PY  - 2023
AB  - Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (combinations) are warranted. Simultaneously, risk assessment is advisable as patient's life expectancy varies between months and decades.We first assess feasibility of RNA-sequencing in a multicenter trial (GMMG-MM5, n=604 patients). Next, we use a clinical routine cohort of untreated symptomatic myeloma patients undergoing autologous stem cell transplantation (n=535, median follow-up (FU) 64 months) to perform RNA-sequencing, gene expression profiling (GEP), and iFISH by ten-probe panel on CD138-purified malignant plasma cells. We subsequently compare target expression to plasma cell precursors, MGUS (n=59), asymptomatic (n=142) and relapsed (n=69) myeloma patients, myeloma cell lines (n=26), and between longitudinal samples (MM vs. relapsed MM). Data are validated using the independent MMRF CoMMpass-cohort (n=767, FU 31 months).RNA-sequencing is feasible in 90.8
KW  - RNA-sequencing (Other)
KW  - immunotherapeutic targets (Other)
KW  - multiple myeloma (Other)
KW  - personalized treatment (Other)
KW  - proliferation (Other)
KW  - risk-adapted treatment (Other)
KW  - survival (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38035078
C2  - pmc:PMC10684778
DO  - DOI:10.3389/fimmu.2023.1286700
UR  - https://inrepo02.dkfz.de/record/285713
ER  -